Top View
- Translating Cancer Biology Into Medicines
- The Royal Marsden NHS Foundation Trust Drug & Therapeutic Committee Minutes 29Th January 2020
- Lists of Medicinal Products for Rare Diseases in Europe*
- Phase 1 Trial of Olaparib and Oral Cyclophosphamide in BRCA Breast Cancer, Recurrent BRCA Ovarian Cancer, Non-BRCA Triple-Negati
- Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation
- BRCA Breast Cancer, Recurrent BRCA Ovarian Cancer, Non-BRCA Triple-Negative Breast Cancer, and Non-BRCA Ovarian Cancer
- PARP Inhibitors As Therapeutics: Beyond Modulation of Parylation
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Olaparib (LYNPARZA) Drug Monograph
- PARP Inhibitors for BRCA1/2-Mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions
- Lynparza, INN-Olaparib
- Synergistic Effect of Arsenic Trioxide, Vismodegib and Temozolomide on Glioblastoma
- Separately Chargeable Drugs List
- BKM120 Sensitizes BRCA-Proficient Triple Negative Breast Cancer Cells To
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, Or Fallopian Tube Canc
- The Role of PALB2 in BRCA1/2-Mediated DNA Repair and Tumor Suppression DISSERTATION Presented in Partial Fulfillment of the Requ
- PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
- The HRD Decision--Which PARP Inhibitor to Use for Whom and When
- Targeted Therapies for Ewsr1-Fli1 Translocated Ewing Family of Tumors
- PARP Inhibitors in Prostate Cancer KABIR GREWAL 1, KAYANAAT GREWAL 2 and IMAD A
- Lynparza, INN-Olaparib
- PARP Inhibitors for Small Cell Lung Cancer and Their Potential for Integration Into Current Treatment Approaches
- Product Monograph
- Olaparib (Lynparza) for Metastatic Breast Cancer with Germline BRCA Mutation – Second Line
- Q2 2021 Results Investor Presentation
- PARP Inhibitors: Their Role Across Tumor Types
- LYNPARZA (Olaparib) RATIONALE for INCLUSION in PA PROGRAM
- Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- Lynparza 100 Mg Film-Coated Tablets
- LYNPARZA® Olaparib Tablets
- WO 2014/152330 Al 25 September 2014 (25.09.2014) P O P C T
- Olaparib Synergizes the Anticancer Activity of Daunorubicin Via Interaction with AKR1C3
- 12475-RW-2019.Pdf
- PRAC Agenda 06-09 July 2020
- 206162Orig1s000
- PARP Inhibitors in Pancreatic Cancer: Molecular Mechanisms and Clinical
- PARP Inhibitors: the Race Is On
- 206162Orig1s000
- CY 2017 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2017
- Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
- Immunotherapy in Advanced Prostate Cancer
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- Targeting NAD+/PARP DNA Repair Pathway As a Novel Therapeutic
- Lynparza (Olaparib) Tablets for Oral Use Contain 100 Mg Or 150 Mg of Olaparib
- Analysis of PARP Inhibitor Toxicity by Multidimensional fluorescence Microscopy Reveals Mechanisms of Sensitivity and Resistance
- Do Not Tube List
- LYNPARZA (Olaparib)
- All ETCTN Trials
- Drug Niraparib Olaparib Niraparib1 Olaparib2,5
- Inhibitors of Nucleotide Excision Repair Decrease UVB-Induced Mutagenesis—An in Vitro Study
- 208558Orig1s000
- Parp Inhibitor Synergizes the Therapeutic Efficacy of Doxorubicin in the Treatment of Prostate Cancer
- Study Protocol and Statistical Analysis Plan
- Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer
- Olaparib (Capsule)
- And Chronic Myelomonocytic Leukemia (CMML)
- Minutes PRAC Meeting on 14 -17 April 2020
- LYNPARZA Safely and Effectively